Critical appraisal of the use of regorafenib in the management of colorectal cancer

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 49-55

  Festino, Lucia ^a   Fabozzi, Alessio ^a   Manzo, Anna ^a   Gambardella, Valentina ^a   Martinelli, Erika ^a   Troiani, Teresa ^a   De Vita, Ferdinando ^a   Orditura, Michele ^a   Ciardiello, Fortunato ^a   Morgillo, Floriana ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Angiogenesis; Colorectal cancer; Regorafenib

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE; REGORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; COLORECTAL CANCER; DESQUAMATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG HEMORRHAGE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SEIZURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; TREATMENT DURATION;

EID: 84876194212     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S34281     Document Type: Review

References (33)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127:2893-2917.
2. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207-219.
3. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol. 2005;23:5374-5385.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
6. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
8. Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001;85(5):692-696.
9. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
11. Ferrara N. VEGF and the quest for tumor angiogenesis factor. Nat Rev Cancer. 2002;2(10):795-803.
12. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579-591.
13. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
14. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
15. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009;8:580-588.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
17. Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol. 2007;33:7-15.
18. Saito M, Watanabe J, Fujisawa T, et al. Angiopoietin-1, 2 and Tie2 expressions in endometrial adenocarcinoma-the Ang2 dominant balance up-regulates tumor angiogenesis in the presence of VEGF. Eur J Gynaecol Oncol. 2006;27:129-134.
19. Szarvas T, Jager T, Totsch M, et al. Angiogenic switch of angiopoietins-Tie2system and its prognostic value in bladder cancer. Clin Cancer Res. 2008;14:8253-8262.
20. Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol. 2009;77:297-309.
21. Nikiforov YE. Thyroid carcinoma:molecular pathways and therapeutic targets Mod Pathol. 2008;21Suppl 2:37-43.
22. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17:3-7.
23. Heinrich MC, Blanke CD, Drucker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20(6):1692-1703.
24. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
25. Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Ann Oncol. 2011;22:22.
26. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic a line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;Suppl 23:Abstract 3.
27. Mross K, Buchert M, Fasol U, et al. A preliminary report of a phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment-a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Int J Clin Pharmacol Ther. 2011;1:96-98.
28. Siu LL, Shapiro J, Jonker J et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wildtype (WT) colorectal carcinoma (CRC): the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol. 2012;30(Suppl 4):386.
29. Scott M, Wilhelm SM, Dumas J, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-255.
30. Mross K, Frost A, Steinbild S, Hedbom S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658-2667.
31. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722-1777.
32. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013; 381(9863):303-312.
33. Waddell T, Cunningham D. Evaluation of regorafenib in colorectal cancer and GIST. Lancet Oncol. 2013;381(9863):273-275.